Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2015

View Archived Issues

Bristol-Myers Squibb updates activities of fourth quarter 2014

Nanoliposomal irinotecan injection improves overall survival and objective response

Agios Pharmaceuticals discloses new inhibitors of mutant IDH2

Investigators in Japan patent novel P2X4 antagonists for pain

Biotie Therapies reports topline results from nepicastat study in cocaine dependence

New anti-IAPP MAbs disclosed by Neotope

Researchers prepare new synthetic vaccines for streptococcal infections

Roche reviews developments of fourth quarter 2014

Prezcobix approved in the U.S. for the treatment of adults with HIV-1

Astellas and Immunomic Therapeutics enter into agreement for JRC2-LAMP-vax

Valeant enters agreement to acquire Dendreon assets

Enrollment in phase IIb study of Ovasave for refractory Crohn's disease triggers payment to TxCell

Nuvo Research reports topline results of phase II WF-10 trial in allergic rhinitis

AstraZeneca, MD Anderson enter into collaboration for ovarian/gynecologic cancers

MicroConstants China in-licenses global rights to AA98 antibody-drug candidates

Sumitomo Dainippon Pharma reviews activities of third quarter of fiscal 2014

OPKO Health submits IND to begin phase IIa study of Factor VIIa-CTP

FDA approves Vyvanse for binge eating disorder

Xiapex approved in E.U. for Peyronie's disease

FDA approves first drug for Waldenstrom's macroglobulinemia

Pluristem releases further results from phase I/II trial of PLX-PAD in surgical muscle injury

Xencor reports results of study on XmAb-7195 in healthy volunteers

Breakthrough therapy designation granted Genentech's MPDL-3280A

Xencor releases topline phase Ib/IIa data for XmAb-5871

Management diagnostics receive two FDA orphan drug status

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...